08/07
AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China
Xiamen, China, 8 July, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that recently it signed an agreement with AstraZeneca to work together closely for the molecular diagnosis of patients with cancer.
22/05
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
24/03
AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market
Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa
14/03
Latest News: Amoy Diagnostics born another clinical detecting center
Shanghai Xiawei Biotechnology Co. Laboratory (hereinafter referred to as "Shanghai Xiawei") under Amoy Diagnostics passed the examination of Shanghai Municipal Health Commission and was granted the "Practice License for Medical Institutions".
20/01
AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center
AmoyDx won the Second Prize of National Scientific and Technological Progress Award; AmoyDx Technology Center is qualified as "National Enterprise Technology Center".
25/11
AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement
Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i
Inquiry
* Required information
Manage your account info
Change your password